Subscribe To
Barrack, rodos and bacine investigates waldencast plc (“wald”)
PHILADELPHIA, Aug. 15, 2023 (GLOBE NEWSWIRE) — Barrack, rodos & Bacine is investigating potential cla...
August 15, 2023, 3:50 pm
What will catalyze psychedelic stocks?
Psychedelics being pulled into the mainstream by medical research. Filament Health CEO Benjamin Lightburn on clinical trials, mic...
May 21, 2023, 7:30 pm
Barrack, rodos & bacine is investigating acacia research corporation (nasdaq: actg) for potential investor claims
PHILADELPHIA, Jan. 06, 2023 (GLOBE NEWSWIRE) — Barrack, rodos & Bacine is investigating Acacia Resear...
January 6, 2023, 8:46 pm
Wellbeing digital sciences says kgk subsidiary gets ok to proceed with phase ii a clinical trial assessing psilocybin therapy for fragile x syndrome
Wellbeing Digital Sciences Inc (NEO:MEDI.AQN, OTCQB:KONEF) announced that its wholly-owned subsidiary KGK Sciences Inc has received a 'No Objection le...
December 23, 2022, 6:44 am
Equity alert: barrack, rodos & bacine files securities class action lawsuit against f45 training holdings, inc. (nyse: fxlv)
PHILADELPHIA, Dec. 08, 2022 (GLOBE NEWSWIRE) — Barrack, rodos & Bacine has commenced a securities cla...
December 8, 2022, 8:12 pm
Wellbeing digital sciences subsidiary kgk science submits psilocybin and fragile x syndrome clinical trial application for client nova mentis
Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) Inc said its wholly-owned subsidiary KGK Science Inc has submitted a clinical trial applicatio...
November 30, 2022, 9:21 am
Mydecine innovations announces inclusion of molecule with improved heart-safe microdose properties in its family of psilocin analogs
Mydecine Innovations Group Inc (OTC:MYCOF, NEO:MYCO) has announced the inclusion of a novel molecule with potentially heart-safe mic...
February 16, 2022, 8:53 am
Mydecine innovations announces inclusion of molecule with improved heart-safe microdose properties in its family of psilocin analogs
Mydecine Innovations Group Inc (OTC:MYCOF, NEO:MYCO) has announced the inclusion of a novel molecule with potentially heart-safe mic...
February 16, 2022, 8:53 am
Mydecine innovations announces inclusion of molecule with improved heart-safe microdose properties in its family of psilocin analogs
Mydecine Innovations Group Inc (OTC:MYCOF, NEO:MYCO) has announced the inclusion of a novel molecule with potentially heart-safe mic...
February 16, 2022, 8:53 am
Mindset pharma identifies additional drug candidates from 'family 3' compounds
Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) announced that it has synthesized additional promising candidates from its Family 3 of next-generation drug...
February 3, 2022, 8:49 am
Mindset pharma identifies additional drug candidates from 'family 3' compounds
Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) announced that it has synthesized additional promising candidates from its Family 3 of next-generation drug...
February 3, 2022, 8:49 am
Mindset pharma identifies additional drug candidates from 'family 3' compounds
Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) announced that it has synthesized additional promising candidates from its Family 3 of next-generation drug...
February 3, 2022, 8:49 am
Mindmed advances phase 2a lsd microdose trial for adult adhd
Neuro-pharmaceutical and psychedelics company Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) announced Friday the initiation of Phase 2a proo...
December 17, 2021, 1:16 pm
Mindmed advances phase 2a lsd microdose trial for adult adhd
Neuro-pharmaceutical and psychedelics company Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) announced Friday the initiation of Phase 2a proo...
December 17, 2021, 1:16 pm
Mindmed advances phase 2a lsd microdose trial for adult adhd
Neuro-pharmaceutical and psychedelics company Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) announced Friday the initiation of Phase 2a proo...
December 17, 2021, 1:16 pm